The Recall Desk
Agency classClass IIOur severity:SevereFDA (Devices)·Z-0317-2027·Announced 2026-11-11

Accriva Hemochron Jr. APTT Test Cuvettes Recalled for Reagent Defect

Accriva Diagnostics is recalling Hemochron Jr. APTT test cuvettes due to a mispositioned or absent clot activating reagent that may cause erroneous high results.

The agency’s classification

FDA (Devices): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as Class II by the FDA. The source describes a hazard where erroneous test results could lead to inadequate anticoagulant therapy and thrombosis, but it does not report any illnesses, injuries, or deaths.

Plain-English summary

Accriva Diagnostics, Inc. is recalling 28,710 units of the Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103. The recall involves specific lots with expiration dates ranging from October 2026 to April 2027. The product was distributed nationwide in the United States and in China and Colombia.

The recall is being conducted because the microcoagulation test, used to evaluate low-dose heparin anticoagulation, may have a mispositioned or absent clot activating reagent. This defect may result in out-of-range high error codes or erroneously high test results. Such errors may lead to retesting or an overestimation of a patient's anticoagulation status, potentially resulting in inadequate anticoagulant therapy and an increased risk of thrombosis.

Healthcare facilities and users of the Hemochron Jr. system should stop using the affected cuvettes and contact Accriva Diagnostics for instructions on returning the product. The source text does not report any illnesses, injuries, or deaths associated with this recall.

The recalled product

Product
Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103
Affected units
28,710

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (6)

  • UDI-DI: 10711234103012
  • Lot(Expiration): B6JCA005(02/28/2027)
  • C6JCA008(03/31/2027)
  • D6JCA011(04/30/2027)
  • K5JCA041(10/31/2026)
  • C6JCA007(03/31/2027)

Distribution

Distributed nationwide across the United States.

The notice also names 9 states specifically:

Similar recalls